{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:36:59Z","timestamp":1770417419217,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anaemia is a common complication of chronic kidney disease (CKD) impacting clinical outcomes and quality of life (QoL). Despite available treatment options, unmet needs exist, especially in relation to QoL. We aimed to develop a consensus of European nephrologists\u2019 opinion on the management of anaemia of CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Seventy-six nephrologists from seven European countries participated in a modified Delphi panel, consisting of two survey rounds followed by an online consensus meeting. Consensus was defined as\u2009\u2265\u200980% agreement or disagreement. The responses were initially assessed against the KDIGO 2012 guideline and reassessed against the draft KDIGO 2025 guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Panellists did not reach consensus on current guidelines being easy to implement or adequately considering patient needs, noting that updates are still needed. Patients with chronic inflammation, infection, erythropoiesis-stimulating agent (ESA)\u00a0resistance, or cancer were identified as populations with unmet needs. Consensus was reached that patients should be more involved in decision-making regarding therapy options. Health-related QoL (HRQoL) was acknowledged as important in the management but no consensus was reached on the use of validated HRQoL tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>European nephrologists believe that existing clinical practice guidelines are not sufficient for the management of patients with anaemia of CKD, especially in those with ESA hyporesponsiveness, infection, chronic inflammation, and malignancy. Unmet needs exist in personalized care, particularly with regard to involving patients and carers in clinical management decisions and using HRQoL tools in routine care. There are no substantial changes in the draft KDIGO 2025 guideline to adequately address the unmet needs identified here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-025-02422-2","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:11:36Z","timestamp":1761325896000},"page":"2851-2860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A European Delphi study on the management of anaemia of CKD: unmet needs in personalized treatment"],"prefix":"10.1093","volume":"38","author":[{"given":"Indranil","family":"Dasgupta","sequence":"first","affiliation":[{"name":"https:\/\/ror.org\/014ja3n03 grid.412563.7 0000 0004 0376 6589 University Hospitals Birmingham Birmingham UK 1"},{"name":"https:\/\/ror.org\/03angcq70 grid.6572.6 0000 0004 1936 7486 School of Health Sciences University of Birmingham Birmingham UK 2"},{"name":"https:\/\/ror.org\/01a77tt86 grid.7372.1 0000 0000 8809 1613 Warwick Medical School University of Warwick Coventry UK 3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Minutolo","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/02kqnpp86 grid.9841.4 0000 0001 2200 8888 Nephrology Division, Department of Advanced Medical and Surgical Sciences University of Campania Luigi Vanvitelli Naples Italy 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Bell","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/03h2bxq36 grid.8241.f 0000 0004 0397 2876 Division of Population Health and Genomics University of Dundee Dundee UK 5"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volkan","family":"Eken","sequence":"additional","affiliation":[{"name":"GSK Pharma Middlesex, London UK 6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Heirman","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/00n3pea85 grid.425090.a 0000 0004 0468 9597 GSK Pharma Wavre Walloni\u00eb Belgium 7"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Peatman","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/00egpfv87 grid.431089.7 0000 0004 0421 8795 Adelphi Values PROVE Bollington Cheshire UK 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Perry","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/00egpfv87 grid.431089.7 0000 0004 0421 8795 Adelphi Values PROVE Bollington Cheshire UK 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Emilio","family":"S\u00e1nchez-\u00c1lvarez","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/03yw66316 grid.414440.1 0000 0000 9314 4177 Hospital Cabue\u00f1es Asturias Spain 9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sapna","family":"Shah","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/01n0k5m85 grid.429705.d 0000 0004 0489 4320 Kings College Hospital NHS Foundation Trust London UK 10"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medi","family":"Stone","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/00egpfv87 grid.431089.7 0000 0004 0421 8795 Adelphi Values PROVE Bollington Cheshire UK 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo Antonio","family":"Ure\u00f1a Torres","sequence":"additional","affiliation":[{"name":"AURA Nord Saint-Ouen France 11"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Val-Mara\u00f1es","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/00egpfv87 grid.431089.7 0000 0004 0421 8795 Adelphi Values PROVE Bollington Cheshire UK 8"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6763-5914","authenticated-orcid":false,"given":"Thilo","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"https:\/\/ror.org\/02gm5zw39 grid.412301.5 0000 0000 8653 1507 Division of Nephrology and Clinical Immunology Uniklinik of the RWTH Aachen Aachen Germany 12"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026020606013089300_CR1","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s12325-017-0566-z","article-title":"Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease","volume":"34","author":"Covic","year":"2017","journal-title":"Adv Ther"},{"key":"2026020606013089300_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"2026020606013089300_CR3","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Sec Nephrology"},{"key":"2026020606013089300_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2369-14-24","article-title":"Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data","volume":"14","author":"Dmitrieva","year":"2013","journal-title":"BMC Nephrol"},{"key":"2026020606013089300_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ahj.2005.03.055","article-title":"Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) study","volume":"151","author":"Astor","year":"2006","journal-title":"Am Heart J"},{"key":"2026020606013089300_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-016-0312-9","article-title":"Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia","volume":"17","author":"Eriksson","year":"2016","journal-title":"BMC Nephrol"},{"key":"2026020606013089300_CR7","doi-asserted-by":"publisher","first-page":"7692376","DOI":"10.1155\/2020\/7692376","article-title":"The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes\u2014a systematic literature review","volume":"2020","author":"Palaka","year":"2020","journal-title":"Int J Nephrol"},{"key":"2026020606013089300_CR8","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2026020606013089300_CR9"},{"key":"2026020606013089300_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026020606013089300_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2026020606013089300_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae205","article-title":"Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance","volume":"17","author":"Dasgupta","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026020606013089300_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.7326\/M15-1839","article-title":"The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis","volume":"164","author":"Collister","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026020606013089300_CR14","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"2026020606013089300_CR15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"2026020606013089300_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad298","article-title":"Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations","author":"Sackeyfio","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026020606013089300_CR17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2026020606013089300_CR18"},{"key":"2026020606013089300_CR19","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026020606013089300_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.ackd.2008.12.009","article-title":"Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation","volume":"16","author":"Adamson","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026020606013089300_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2147\/IJNRD.S239151","article-title":"Erythropoietin resistance in patients with chronic kidney disease: current perspectives","volume":"13","author":"Santos","year":"2020","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026020606013089300_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2026020606013089300_CR23","first-page":"936","article-title":"A systematic review: how to choose appropriate health-related quality of life (HRQOL) measures in routine general practice?","volume":"6","author":"Tian-hui","year":"2005","journal-title":"J Zhejiang Univ Sci B"},{"key":"2026020606013089300_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"2026020606013089300_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12882-021-02489-6","article-title":"Person centred care provision and care planning in chronic kidney disease: which outcomes matter? A systematic review and thematic synthesis of qualitative studies : Care planning in CKD: which outcomes matter?","volume":"22","author":"de Jong","year":"2021","journal-title":"BMC Nephrol"},{"key":"2026020606013089300_CR26","doi-asserted-by":"publisher","first-page":"e067044","DOI":"10.1136\/bmjopen-2022-067044","article-title":"Discussing results of patient-reported outcome measures (PROMs) between patients and healthcare professionals in routine dialysis care: a qualitative study","volume":"12","author":"Willik","year":"2022","journal-title":"BMJ Open"},{"key":"2026020606013089300_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2258986","article-title":"An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease","volume":"45","author":"Zhao","year":"2023","journal-title":"Ren Fail"},{"issue":"10","key":"2026020606013089300_CR28","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026020606013089300_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12882-022-02969-3","article-title":"Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel","volume":"23","author":"Mazzaferro","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026020606013089300_CR30","first-page":"79","article-title":"Anemia and iron deficiency diagnosis, management and treatment in chronic kidney disease\u2014consensus and agreement through a Delphi panel","volume":"34","author":"Ferreira","year":"2020","journal-title":"Port J Nephrol Hypertens"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02422-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/9\/2851\/66793777\/joneph_38_9_2422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02422-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/9\/2851\/66793777\/joneph_38_9_2422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:01:39Z","timestamp":1770375699000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/9\/2851\/8462643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02422-2","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,1]]},"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.D., R.M., S.B., P.A.U.T., S.S. and T.K. received honoraria from GSK for serving in the steering committee of this project, but did not receive any fee for writing the manuscript. I.D. has received research grants from Baxter, Sanofi, and Medtronic; has been on advisory boards of GSK, Sanofi, AstraZeneca, and Vifor; and has received honoraria from GSK, Sanofi, AstraZeneca, and Vifor for consultation and speaker meetings. R.M. has been a member of advisory boards for Amgen, Astellas, and GSK; has received consulting fees from Bayer and GSK; and has been an invited speaker at meetings supported by Amgen, Astellas, Bayer, Vifor, and AstraZeneca. T.K. has been a member of advisory boards for AstraZeneca, Vifor, and GSK; has received consulting fees from Bayer, Hexal, Vifor, and GSK; and has been an invited speaker at meetings supported by GSK. P.A.U.T. declares receipt of advisory and\/or lecture fees from Astellas, AstraZeneca, GSK, Hemotech, Sanofi, Th\u00e9radial, and Vifor. S.B. has received consultancy fees from GSK, AstraZeneca, and Bayer. S.S. has received consultancy fees from Astellas, Biotest, Takeda, Medice, and GSK. N.H. and V.E. are employees and shareholders of GSK. R.P., M.S., L.V.M., and J.P. are employees of Adelphi Values PROVE\u2122; Adelphi Values PROVE\u2122 received funding from GSK to conduct the Delphi study through to manuscript development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As the study did not involve human participants, no ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Healthcare professionals\/panellists consented to anonymous publication of their statements and of the results of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}